We follow industry news and trends so you can stay ahead of the game. Subscribe to receive emails regarding policies and findings that impact you and your business.

Already a subscriber and want to update your preferences? Click here.

BACK TO NEWS

MEDIA MENTIONS

SEP 1 2017

Mixed Signals on Innovative Rx Drug Pay Arrangements - Bloomberg BNA

William Garvin, Shareholder in the firm's FDA & Biotechnology section, comments on the outcomes-based payment arrangement for a new drug to treat pediatric and young adult leukemia patients in Bloomberg BNA's "Mixed Signals on Innovative Rx Drug Pay Arrangements."